RSS-Feed abonnieren
DOI: 10.1055/a-2693-8599
Impact of Labor in Primary Cesarean Delivery on Subsequent Risk of Placenta Accreta
Authors

Abstract
Objective
This study aimed to evaluate whether a primary cesarean delivery (CD) performed during labor increases the risk of placenta accreta spectrum (PAS) disorders in a high-parity population with a low overall CD rate.
Study Design
This retrospective cohort study included singleton pregnancies with a confirmed International Federation of Gynecology and Obstetrics (FIGO) PAS diagnosis at a single tertiary center (2011–2022). Each PAS case was matched 1:1 to a control without PAS based on parity, number of previous CDs, and history of vaginal birth after cesarean. Multivariable logistic regression assessed the association between labored versus unlabored primary CD and PAS, adjusting for placenta previa, in vitro fertilization, prior postpartum hemorrhage, and prior dilation and curettage.
Results
Among 128,485 deliveries, 45 PAS cases (0.04%) were identified and matched to 45 controls. Median parity was 5.0; 34% had three or more prior CDs. Labored primary CD was associated with increased PAS risk (adjusted odds ratio: 6.3, 95% confidence interval [CI]: 1.7–23.3; p < 0.05). Placenta previa and prior postpartum hemorrhage were also independently associated with PAS. No significant differences in maternal or neonatal outcomes were observed between the labored and elective primary cesarean groups.
Conclusion
Primary CD during labor increases PAS risk six-fold in subsequent pregnancies, warranting consideration in counseling and surgical decision-making.
Key Points
-
A labored CD raises the risk of PAS in the next pregnancy by sixfold.
-
No significant differences in maternal or neonatal outcomes in subsequent pregnancy between labored and unlabored cesarean sections.
-
The study highlights the importance of recognizing labored cesarean section as a PAS risk factor in future pregnancies.
Keywords
placenta accreta spectrum - labored cesarean delivery - elective cesarean delivery - risk factorsPublikationsverlauf
Eingereicht: 03. Juli 2025
Angenommen: 01. September 2025
Artikel online veröffentlicht:
16. September 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Afshar Y, Dong J, Zhao P. et al. Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders. Nat Commun 2021; 12 (01) 4408
- 2 Carusi DA, Duzyj CM, Hecht JL. et al; Pan-American Society for the Placenta Accreta Spectrum. Knowledge gaps in placenta accreta spectrum. Am J Perinatol 2023; 40 (09) 962-969
- 3 Afshar Y, Yin O, Jeong A. et al. Placenta accreta spectrum disorder at single-cell resolution: a loss of boundary limits in the decidua and endothelium. Am J Obstet Gynecol 2024; 230 (04) 443.e1-443.e18
- 4 Silver RM, Landon MB, Rouse DJ. et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107 (06) 1226-1232
- 5 Einerson BD, Comstock J, Silver RM, Branch DW, Woodward PJ, Kennedy A. Placenta accreta spectrum disorder: Uterine dehiscence, not placental invasion. Obstet Gynecol 2020; 135 (05) 1104-1111
- 6 Eller AG, Porter TF, Soisson P, Silver RM. Optimal management strategies for placenta accreta. BJOG 2009; 116 (05) 648-654
- 7 Afshar Y, Kashani Ligumsky L, Bartels HC, Krakow D. Biology and pathophysiology of placenta accreta spectrum disorder. Obstet Gynecol 2025; 145 (06) 611-620
- 8 Kashani-Ligumsky L, Scott O, Martinez G. et al. Updates and knowledge gaps in placenta accreta spectrum biology. Clin Obstet Gynecol 2025; 68 (02) 310-316
- 9 Goh W, Yamamoto SY, Thompson KS, Bryant-Greenwood GD. Relaxin, its receptor (RXFP1), and insulin-like peptide 4 expression through gestation and in placenta accreta. Reprod Sci 2013; 20 (08) 968-980
- 10 Einerson BD, Gilner JB, Zuckerwise LC. Placenta accreta spectrum. Obstet Gynecol 2023; 142 (01) 31-50
- 11 Bailit JL, Grobman WA, Rice MM. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol 2015; 125 (03) 683-689
- 12 Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177 (01) 210-214
- 13 Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol 2005; 192 (05) 1458-1461
- 14 Read JA, Cotton DB, Miller FC. Placenta accreta: changing clinical aspects and outcome. Obstet Gynecol 1980; 56 (01) 31-34
- 15 Eshkoli T, Weintraub AY, Sergienko R, Sheiner E. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. Am J Obstet Gynecol 2013; 208 (03) 219.e1-219.e7
- 16 Silver RM, Branch DW. Placenta accreta spectrum. N Engl J Med 2018; 378 (16) 1529-1536
- 17 Klar M, Michels KB. Cesarean section and placental disorders in subsequent pregnancies–a meta-analysis. J Perinat Med 2014; 42 (05) 571-583
- 18 Wang-Koehler E, Pineles BL. Letter to the editor regarding “Risk factors for placenta accreta spectrum disorder among patients with placenta previa and prior cesarean delivery”. Am J Obstet Gynecol MFM 2024; 6 (07) 101380
- 19 Bowman ZS, Eller AG, Bardsley TR, Greene T, Varner MW, Silver RM. Risk factors for placenta accreta: a large prospective cohort. Am J Perinatol 2014; 31 (09) 799-804
- 20 Salmanian B, Fox KA, Arian SE. et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am J Obstet Gynecol 2020; 223 (04) 568.e1-568.e5
- 21 Kaser DJ, Melamed A, Bormann CL. et al. Cryopreserved embryo transfer is an independent risk factor for placenta accreta. Fertil Steril 2015; 103 (05) 1176-84.e2
- 22 Zeevi G, Tirosh D, Baron J, Sade MY, Segal A, Hershkovitz R. The risk of placenta accreta following primary cesarean delivery. Arch Gynecol Obstet 2018; 297 (05) 1151-1156
- 23 Kamara M, Henderson JJ, Doherty DA, Dickinson JE, Pennell CE. The risk of placenta accreta following primary elective caesarean delivery: a case-control study. BJOG 2013; 120 (07) 879-886
- 24 Colmorn LB, Krebs L, Klungsøyr K. et al. Mode of first delivery and severe maternal complications in the subsequent pregnancy. Acta Obstet Gynecol Scand 2017; 96 (09) 1053-1062
- 25 O'Malley KN, Norton ME, Osmundson SS. Effect of trial of labor before cesarean and risk of subsequent placenta accreta spectrum disorders. Am J Perinatol 2020; 37 (06) 633-637
- 26 Romero R, Sabo Romero V, Kalache KD, Stone J. Parturition at term: induction, second and third stages of labor, and optimal management of life-threatening complications-hemorrhage, infection, and uterine rupture. Am J Obstet Gynecol 2024; 230 (3S): S653-S661
- 27 Pique-Regi R, Romero R, Tarca AL. et al. Single cell transcriptional signatures of the human placenta in term and preterm parturition. eLife 2019; 8: e52004
- 28 Garcia-Flores V, Romero R, Tarca AL. et al. Deciphering maternal-fetal cross-talk in the human placenta during parturition using single-cell RNA sequencing. Sci Transl Med 2024; 16 (729) eadh8335
- 29 Farladansky-Gershnabel S, Levy G, Neiger R. Obstetric complications and pregnancy outcome among grand multiparous women. J Reprod Med 2016; 61 (9-10): 452-456
- 30 Kashani-Ligumsky L, Cohen R, Many A, Elmalech A, Neiger R, Lopian M. High-order parity improves the perinatal outcome of twin deliveries. Am J Perinatol 2024; 41 (S 01): e1486-e1490
- 31 Kashani-Ligumsky L, Neiger R, Segal E, Cohen R, Lopian M. Is parity a risk factor for late preterm birth? Results from a large cohort study. J Clin Med 2024; 13 (02) 429
- 32 Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet 2019; 146 (01) 20-24
- 33 De Oliveira Carniello M, Oliveira Brito LG, Sarian LO, Bennini JR. Diagnosis of placenta accreta spectrum in high-risk women using ultrasonography or magnetic resonance imaging: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2022; 59 (04) 428-436
- 34 Thomson AJ, Telfer JF, Young A. et al. Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. Hum Reprod 1999; 14 (01) 229-236
- 35 Carusi D. Placenta accreta: Epidemiology and risk factors. Clin Obstet Gynecol 2017; 61: 733-742
- 36 Sholapurkar SL. Increased incidence of placenta praevia and accreta with previous caesareans–a hypothesis for causation. J Obstet Gynaecol 2013; 33 (08) 806-809
- 37 Abalos E, Addo V, Brocklehurst P. et al; CORONIS collaborative group. Caesarean section surgical techniques: 3 year follow-up of the CORONIS fractional, factorial, unmasked, randomised controlled trial. Lancet 2016; 388 (10039): 62-72
- 38 Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol 2018; 218 (01) 75-87
- 39 Jauniaux E, Burton GJ. Pathophysiology of placenta accreta spectrum disorders: A review of current findings. Clin Obstet Gynecol 2018; 61 (04) 743-754
- 40 Debras E, Capmas P, Maudot C, Chavatte-Palmer P. Uterine wound healing after caesarean section: A systematic review. Eur J Obstet Gynecol Reprod Biol 2024; 296: 83-90